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Background: In	children	aged	<5	years	 in	whom	severe	 respiratory	syncytial	virus	
(RSV)	episodes	predominantly	occur,	there	are	currently	no	appropriate	standardised	
instruments	to	estimate	quality	of	life	years	(QALY)	loss.
Objectives: We	 estimated	 the	 age‐specific	 QALY	 loss	 due	 to	 RSV	 by	 developing	
a	 regression	model	which	predicts	 the	QALY	 loss	without	 the	use	of	standardised	
instruments.
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1  | INTRODUC TION
Respiratory	syncytial	virus	(RSV)	is	a	leading	cause	of	lower	respira‐
tory	tract	 infection	 in	 infants,	accounting	for	more	than	three	mil‐
lion	hospital	admissions	and	60	000	deaths	in	hospitals	for	children	
less	than	5	years	of	age	in	2015.1,2	The	health	burden	of	RSV	is	high	








expressed	 in	 terms	 of	 quality	 of	 life	 year	 (QALY)	 loss.4	QALY	 loss	
for	 a	 single	 RSV	 episode	 is	 calculated	 by	 integrating	 the	 loss	 of	
health‐related	quality	of	 life	 (HR‐QoL)	over	the	duration	for	which	
the	symptoms	are	experienced.	Health‐related	quality	of	life	is	eval‐
uated	 through	 the	 use	of	 standardised	 and	 validated	 instruments,	






In	 this	 study,	 we	 determined	 the	HR‐QoL	 loss	 due	 to	 an	 RSV	
episode	 in	 individuals	5	years	and	older	with	suspected	RSV	using	
EQ‐5D	 questionnaires.12‐14	 We	 developed	 a	 statistical	 model	 to	
predict	the	HR‐QoL	loss	as	a	function	of	responses	from	a	broader	
health	 and	 healthcare‐seeking	 questionnaire.	 We	 then	 used	 this	
statistical	model	to	estimate	QALY	loss	for	children	and	adults	over	
5	years	of	age.	Finally,	using	the	statistical	model	parameterised	with	






During	 the	 2016‐17	 RSV	 season,	 confirmed	 cases	 of	 RSV	 in	 chil‐
dren	under	 the	age	of	5	years	 from	the	previous	 two	weeks	were	
extracted	on	dates	13th	December,	25th	December	2016	and	3rd	
January	 2017	 from	 the	 Public	 Health	 England	 (PHE)	 Respiratory	
DataMart	surveillance	(RDMS)	system.15	For	all	the	confirmed	cases	
for	whom	 name,	 date	 of	 birth	 and	National	Health	 Service	 (NHS)	




RDMS	 system.	 Each	 questionnaire	 pack	 consisted	 of	 three	 ques‐




household	 members,	 those	 aged	 5‐14	 years	 (5‐14	 Questionnaire)	
and	 those	 aged	 15	 years	 or	 older	 (15+	Questionnaire).	 Suspected	
RSV	cases	were	defined	as	persons	who	share	a	household	with	the	



















in	 the	 Index	Questionnaire,	 the	 5‐14	 and	 the	 15+	Questionnaires	
also	asked	(f)	the	time	taken	off	school/work	due	to	symptoms	(pro‐












2.3 | Statistical model to estimate HR‐QoL
EQ‐5D	questionnaires	are	not	validated	for	children	under	5	years	of	
age	so	we	cannot	obtain	estimates	for	the	peak	HR‐QoL	loss	from	
the	 data	 in	 the	 confirmed	 cases.	 Therefore,	 using	 the	 responses	
from	the	suspected	cases,	we	fitted	a	 regression	model	 to	predict	
the	 (model‐estimated)	 peak	 HR‐QoL	 loss,	 as	 a	 function	 of	 ques‐
tionnaire	 response	 variables:	 age	 (5‐14	years,	 15	 years	 and	older),	
coughing	 severity,	 healthcare‐seeking	 behaviour,	 productivity	 and	
VAS	score	loss	(Appendix	S2	Section	1).	To	fit	the	regression	model,	
we	only	included	responses	from	suspected	cases	which,	in	addition	
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to	 providing	 answers	 to	 the	 aforementioned	 response	 variables,	
completed	all	five	dimensions	of	health	status	in	their	EQ‐5D	ques‐
tionnaires.	 To	 assess	 the	 accuracy	 of	 the	 fitted	 regression	model,	
we	compared	the	peak	HR‐QoL	loss	from	the	response	data	to	the	







2.4 | Quality‐adjusted life year (QALY) loss due to 
an RSV episode
We	estimated	 each	 respondent's	QALY	 loss	 by	multiplying	 their	















that	 the	 ratio	 of	QALY	 loss	 for	 people	who	 seek	 health	 care	 to	
those	that	do	not	is	independent	of	age.







In	 accordance	 with	 The	 Health	 Service	 (Control	 of	 Patient	
Information)	Regulations	2002	No.	1438	Section	251	Regulation	3,	
Public	Health	England	may	process	confidential	patient	information	
with	 a	 view	 to	monitoring	 and	managing;	 outbreaks	 of	 communi‐
cable	disease;	 incidents	of	exposure	 to	communicable	disease	and	
the	delivery,	efficacy	and	safety	of	immunisation	programmes.20	All	











dersampled	 infants	aged	1‐2	months	old	 (Figure	1A,B).	 In	 the	122	






aged	5‐14	years	 and	15	years	 and	older,	 respectively.	Duration	of	
coughing	 was	 provided	 for	 98/122	 (80.3%)	 and	 43/87	 (49.4%)	 of	
confirmed	and	suspected	cases,	respectively.




17/33	 (51.5%)	 children	 aged	 5‐14	 years	 took	 time	 off	 school	 and	
















affected	 usual	 activities	 (72%),	 caused	 pain/discomfort	 (76%)	 and	
anxiety/depression	(84%).	The	EQ‐5D‐3L	responses	for	respondents	
aged	15	years	and	older	suggested	similar	results	with	RSV	affect‐
ing	 respondents'	 usual	 activities	 (54.2%),	 causing	 pain/discomfort	
(36.0%)	and	anxiety	and	depression	 (32.0%)	 (Figure	2).	Converting	
these	EQ‐5D	and	EQ‐5D‐3L	 responses	 using	 the	UK	TTO	 scoring	
tariff,	 the	median	peak	HR‐QoL	weight	 from	 the	data	 for	children	
aged	5‐14	years	old	and	persons	15	years	and	older	was	0.689	(range	
−0.170‐1.000)	 and	 0.752	 (range	 −0.166	 to	 1.000),	 respectively	
(Table	S2).	These	weights	 led	 to	a	median	peak	HR‐QoL	 loss	 from	
the	data	of	0.456	 (range	0.0‐1.170)	 and	0.358	 (range	0‐0.998)	 for	
5‐14	and	15	years	and	older,	respectively.	As	there	was	no	significant	
difference	between	the	peak	HR‐QoL	 loss	from	the	data	between	
5	 and	 14	 years	 old	 and	 persons	 15	 years	 (Kolmogorov‐Smirnov	
 
Aged 0‐4 ya 
(n = 122) (%)
Aged 5‐14 y 
(n = 33) (%)
Aged 15 y and over 
(n = 54) (%)
Symptoms
Runny/blocked	nose 96	(78.7) 28	(84.8) 43	(79.6)
Fever 70	(57.4) 18	(54.5) 22	(40.7)
Coughing 110	(90.2) 27	(81.8) 51	(94.4)
Sore	throat 36	(29.5) 17	(51.5) 38	(70.4)
Coughing	severity
No	effect	on	daily	activities 16	(13.1) 10	(30.3) 8	(14.8)
Mild	effect	on	daily	activities 34	(27.9) 15	(45.5) 32	(59.3)

























Admitted	to	hospital 103	(84.4) 1	(3.0) 1	(1.9)









Baseline	(median,	range) 90	(30‐100) 95	(10‐100) 95	(50‐100)
Worst	day	(median,	range) 20	(0‐85) 50	(5‐85) 50	(0‐90)




TA B L E  1  Summary	of	index,	5‐14	and	
15+	Questionnaire	responses








3.2 | Model‐estimated peak HR‐QoL loss














of	 0.820	 (95%	CI	 0.222‐1.450,	 Table	2;	 Tables	 S2	 and	S3).	 Finally,	
assuming	the	ratio	of	HR‐QoL	loss	for	healthcare‐seeking	cases	to	
non‐health‐seeking	 cases	 is	 independent	 of	 age,	 we	 estimated	 a	
model‐estimated	peak	HR‐QoL	loss	for	under	fives	as	0.539	(95%	CI	
0.144‐0.952,	Table	2;	Tables	S2	and	S3).
3.3 | Quality‐adjusted life years loss
The	daily	RSV	HR‐QoL	weights	from	Flu	Watch18	suggest	that	for	
the	first	half	of	symptom	duration,	the	HR‐QoL	weight	decreases	











































































No problems Some problems Severe problems
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the	weighted	HR‐QoL	 loss	 by	multiplying	 the	HR‐QoL	 loss	 by	 a	
constant	scaling	factor	of	0.25	(Appendix	S2	Section	3).	Finally,	to	
calculate	the	estimated	QALY	loss	per	RSV	episode,	we	multiplied	
the	 weighted	 HR‐QoL	 loss	 per	 RSV	 episode	 by	 the	 duration	 of	
symptoms	reported	in	our	questionnaire	responses	(Appendix	S2	
Section	4).	The	duration	of	symptoms	in	children	aged	5‐14	years	







older	 (1.950	×	 10−3	 (95%	CI	 (0.185‐9.578	×	 10−3))).	 For	 individu‐
als	who	did	not	seek	health	care,	the	QALY	loss	per	RSV	episode	
was	 3.024	 ×	 10−3	 (95%	 CI	 0.329‐10.098	 ×	 10−3)	 for	 under	 fives	
and	1.543	×	10−3	 (95%	CI	0.136‐6.406	×	10−3)	 for	 those	5	years	
and older.
3.4 | Healthcare‐seeking and total disease burden
The	 total	 number	 of	 annual	GP	 consultations	 and	 hospital	 admis‐
sions	 due	 to	 RSV	 in	 England	 is	 855	 000	 and	 375	 000‐383	 000	


















health	 care	was	 sought	 and	Visual	Analogue	Scale	 score	 loss.	We	
used	our	novel	statistical	model	 to	evaluate	the	QALY	 loss	 in	chil‐














F I G U R E  3  The	peak	HR‐QoL	loss	from	the	EQ‐5D	questionnaires	(dark	grey)	and	estimated	using	the	statistical	model	(light	grey).	The	
dashed	line	shows	the	mean,	and	solid	thin	lines	indicate	the	upper	and	lower	95%	confidence	interval
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ratio	of	QALY	loss	for	people	over	5	years	who	do	not	seek	health	
care	 to	 those	 that	do	 is	 the	same	 independent	of	age.	However,	
using	 this	 ratio	may	 overestimate	 the	QALY	 loss	 of	 non‐health‐
care‐seeking	cases	in	children	less	than	5	years	of	age,	as	health‐
care‐seeking	cases	in	persons	aged	5	years	and	older	are	generally	
milder	 than	 healthcare‐seeking	 confirmed	 cases	 in	 infants	 less	
than	5	years	old	 (with	decreases	 in	VAS	score	 loss,	coughing	se‐
verity,	 and	 the	 proportion	 admitted	 to	 hospital).	 To	 collect	 data	
directly	on	the	QALY	loss	in	children	under	five	who	do	not	seek	
health	 care	 would	 require	 a	 much	 larger	 and	 more	 intensive	
community‐based	study	with	frequent	testing	throughout	an	RSV	
season.	Second,	suspected	cases	may	have	experienced	non‐RSV	
respiratory	 disease.	However,	 previous	 studies	 have	 shown	 that	




naires	 some	 days	 after	 symptoms	may	 be	 subject	 to	 recall	 bias.	
Our	 estimates	 for	 the	 peak	 HR‐QoL	 life	 loss	 for	 persons	 aged	
15	 years	 and	 older	 (0.452	 (95%	CI	 0.177‐1.222))	 are	 larger	 than	









the	HR‐QoL	 loss	 for	 people	who	 have	 had,	 or	 suspected	 to	 have	










to	 RSV	 in	 young	 children	 for	 whom	 standardised	 instruments	 for	
deriving	HR‐QoL	estimates	are	not	appropriate.	Thus,	our	method	





Our	 RSV‐related	 QALY	 loss	 estimate	 for	 people	 aged	 5	 years	
and	over	is	consistent	to	the	estimates	of	a	prospective	study	that	
estimated	QALY	loss	across	people	of	all	ages	with	non‐confirmed	
Influenza	who	reported	 influenza‐like	 illness	 (ILI)	 (mean	2.6	×	10−3 




the	under	 fives	who	 seek	health	 are	 less	 severe	 than	hospitalised	
influenza	episodes,	(QALY	loss	of	6.0	×	10−3	(range	5.1‐6.9	×	10−3)).23 





and	 older.	 This	 result	 suggests	 that	 neglecting	QALY	 loss	 in	 older	
TA B L E  2  HR‐QoL,	QALD	and	QALY	loss	for	the	confirmed	
cases	in	children	less	than	5	y	of	age,	and	in	the	suspected	cases	in	
children 5 y and older
 Under 5 y of agea




None	or	mild 0.499	(0.148‐1.482) 0.382 
(0.111‐1.113)
Severe 0.878	(0.344‐1.443) 0.785 
(0.280‐1.368)
Healthcare‐seeking	behaviour
None 0.539	(0.144‐0.952)b 0.405 
(0.111‐1.137)




None	or	mild 0.845	(0.097‐3.292) 0.528 
(0.050‐2.167)
Severe 1.496	(0.221‐4.841) 1.103 
(0.126‐4.149)
Healthcare‐seeking	behaviour
None 1.00	(0.141‐3.652)b 0.565 
(0.049‐2.349)
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children	 and	 working‐age	 adults	 might	 substantially	 underesti‐
mate	 the	 impact	 of	 a	 potential	 RSV	 vaccine	 programme.	 Further,	










sons:	 infections	 in	 infants	are	generally	more	severe,	with	higher	
rates	 of	 symptomatic	 infections25	 and	 a	 tendency	 for	 increased	




In	 summary,	we	estimated	 the	QALY	 loss	due	 to	an	RSV	epi‐
sode	in	confirmed	cases	in	children	less	than	5	years	old	and	sus‐
pected	 cases	 in	 persons	 aged	5	 years	 and	older.	Despite	 severe	
RSV	being	associated	with	infants,	we	found	that	RSV	infections	
in	 individuals	aged	5	years	and	older	account	for	54%	of	the	an‐
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